Literature DB >> 15268650

Causality assessment in drug-induced hepatotoxicity.

Raúl J Andrade1, Raquel Camargo, M Isabel Lucena, Rocío González-Grande.   

Abstract

Drugs are currently an important cause of liver disease, ranked as the most frequent reason for acute liver failure. Despite recent advances in knowledge of the mechanisms implicated in drug-induced hepatocellular damage and cholestasis, as well as the identification of several risk factors, the diagnosis of hepatotoxicity remains a difficult task because specific tests are not available. In a step-by-step approach, the incrimination of a drug in liver symptoms requires a high degree of suspicion on the part of the physician, temporal eligibility, awareness of the drug's hepatotoxic potential, the exclusion of alternative causes of liver damage, and the ability to detect the presence of subtle data that favour a toxic aetiology. Ultimately, the use of diagnostic algorithms may add consistency to the diagnostic process either by translating the suspicion into a quantitative score or by providing a framework that emphasises the features that merit attention in cases of suspected hepatic adverse reactions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15268650     DOI: 10.1517/14740338.3.4.329

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  12 in total

1.  Drug-induced cholestatic hepatitis: how late can it occur even after the cessation of the culpable drug?

Authors:  Nasim Zamani; Afshin Mohammad Alizadeh
Journal:  Neuro Oncol       Date:  2012-04-26       Impact factor: 12.300

2.  Herbalife hepatotoxicity: Evaluation of cases with positive reexposure tests.

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Alexander Schwarzenboeck; Axel Eickhoff
Journal:  World J Hepatol       Date:  2013-07-27

3.  Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Allen D Brinker; Jenna Lyndly; Joseph Tonning; David Moeny; Jonathan G Levine; Mark I Avigan
Journal:  Drug Saf       Date:  2013-12       Impact factor: 5.606

4.  Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.

Authors:  Ayako Suzuki; Raul J Andrade; Einar Bjornsson; M Isabel Lucena; William M Lee; Nancy A Yuen; Christine M Hunt; James W Freston
Journal:  Drug Saf       Date:  2010-06-01       Impact factor: 5.606

Review 5.  Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists.

Authors:  Raúl-J Andrade; Mercedes Robles; Alejandra Fernández-Castañer; Susana López-Ortega; M-Carmen López-Vega; M-Isabel Lucena
Journal:  World J Gastroenterol       Date:  2007-01-21       Impact factor: 5.742

Review 6.  Herbal hepatotoxicity: challenges and pitfalls of causality assessment methods.

Authors:  Rolf Teschke; Christian Frenzel; Johannes Schulze; Axel Eickhoff
Journal:  World J Gastroenterol       Date:  2013-05-21       Impact factor: 5.742

Review 7.  Causality assessment in hepatotoxicity by drugs and dietary supplements.

Authors:  Rolf Teschke; Alexander Schwarzenboeck; Karl-Heinz Hennermann
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

Review 8.  Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps.

Authors:  Rolf Teschke; Axel Eickhoff
Journal:  Front Pharmacol       Date:  2015-04-23       Impact factor: 5.810

Review 9.  Hepatic safety of antibiotics used in primary care.

Authors:  Raúl J Andrade; Paul M Tulkens
Journal:  J Antimicrob Chemother       Date:  2011-05-17       Impact factor: 5.790

Review 10.  Management of Pharmacologic Adverse Effects in Advanced Liver Disease.

Authors:  Miren García-Cortés; Alberto García-García
Journal:  Clin Drug Investig       Date:  2022-05-06       Impact factor: 3.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.